You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
News on biomarker discovery and validation for research and diagnostic use in genetics, genomics, and molecular diagnostics.
The companies aim to identify biomarkers that can be used to diagnose early-onset Parkinson's disease, as well as track disease progression.
The Sydney, Australia-based firm has licensed a single biomarker which it plans to develop into a test for triaging COVID-19 patients.
SomaLogic and the FDA will use the company's SomaScan proteomics platform to identify circulating pharmacodynamic biomarkers for biologics.
The drugmaker has a small molecule drug called venglustat under Phase II development for Parkinson's disease patients with a specific genetic mutation.
The companies are currently working together to commercialize their respective products including genetic tests for type 2 diabetes and gestational diabetes risk.
Bloomberg reports AstraZeneca may conduct another study of its candidate SARS-CoV-2 vaccine after dosing error.
Moderna is applying for an Emergency Use Authorization for its coronavirus vaccine, according to the New York Times.
The National Health Service is to conduct a trial of Grail's blood-based screening test for cancer.
In PLOS this week: somatic mutation patterns of glioblastomas among Lebanese patients, phenome-wide study using UK Biobank data, and more.
Recent work by many investigators has discovered that over the course of aging, hematopoietic stem cells (HSCs) commonly undergo clonal expansion.